Summarized by Masters of Longevity from PR Newswire.
Phase 2b data showed slower functional decline and biomarker changes with PrimeC.
Key Takeaways
- Phase 2b was observational and is not causal.
- Biomarker shifts were reported consistent with multi‑target action.
- FDA cleared a pivotal Phase 3 study pending design details.
